You are here

Press Releases

Malvern, Pa., December 11, 2017 — Siemens Healthineers has launched teamplay Cardio, a new cardiology dashboard application within the Siemens Healthineers Digital Ecosystem. Part of teamplay—the company’s cloud-based network that enables access to metrics from a facility’s imaging fleet—this new application helps cardiology departments better understand their performance and status.

ROSEMONT, Ill., Dec. 11, 2017 — Eating yogurt on a regular basis may help reduce measures of chronic inflammation in women and support a healthy digestive system, researchers from University of Wisconsin-Madison College of Agricultural and Life Sciences (UW-Madison) report in the British Journal of Nutrition.

PLAINSBORO, N.J., Dec. 5, 2017 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center has launched the first vascular robotic program in the Houston area with the installation of two CorPath® GRX Systems. In addition and as part of the program launch, Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical research on robotics and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).

BioTelemetry, Inc., the leading mobile and wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today a partnership with Apple to provide cardiac monitoring services in conjunction with the Apple Heart Study.

DUBLIN, Ohio, November 30, 2017 — Cordis, a Cardinal Health company, and Medinol today announced United States Food and Drug Administration (FDA) approval of the EluNIR™ drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries.

MADRID — Nov. 28, 2017 — MedLumics, a medical device company developing an optically guided cardiac ablation platform for the treatment of Atrial fibrillation (AF), announced today it has appointed James Greene as Chief Executive Officer and named Giovanni Leo to the board of directors.

Digisonics and Medis have partnered to provide a comprehensive single system solution that adds cardiac MR to Digisonics congenital Echo and Cath system. 

New York, NY (November, 21, 2017) — This Thanksgiving week, WCBS-TV will air “The Resilient Heart,” a feature documentary that explores the keys to eradicating heart disease on a worldwide scale. The film will air on Friday, November 24, from 10 am to 11 am on WCBS (channel 2) and on Sunday, November 26, from 10 pm to 11 pm on WLNY (channels 10/55).

DUBLIN — November 20, 2017 — Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. commercial launch for its portfolio of Azure(TM) pacemakers with BlueSync(TM)technology.

A new real-world analysis of adults with type 2 diabetes and established cardiovascular disease (CVD) shows adult patients who initiated therapy with INVOKANA® (canagliflozin) or another sodium glucose cotransporter-2 inhibitor (SGLT2i) had a 43 percent reduced risk for all-cause mortality (ACM) and hospitalization for heart failure (HHF) after an average of 1.6 years, compared to similar patients who initiated treatment with a non-SGLT2i medication using an intent-to-treat (ITT) approach.

SILVER SPRING, Md., Nov. 16, 2017 — The U.S. Food and Drug Administration today approved Hemlibra (emicizumab-kxwh) to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.

RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2017 — New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. 

THOUSAND OAKS, Calif., Nov. 13, 2017 — Amgen (NASDAQ:AMGN) today announced five new subgroup analyses from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) that showed the addition of Repatha to statin therapy improved clinical outcomes with significant reduction of cardiovascular (CV) events, such as heart attack (also called myocardial infarction or MI) and stroke, in high-risk patients with peripheral artery disease (PAD), and in patients with a history of heart attack.

The Centers for Medicare & Medicaid Services (CMS) today finalized its rule for the Merit-Based Incentive Payment System (MIPS) and Advanced Alternative Payment Models (APMs) that AMGA contends will slow the transition to value.

Medtronic plc (NYSE:MDT) announces the release of its fiscal year 2017 Integrated Performance Report. The report highlights the combined financial, social, and environmental impact of Medtronic.

DUBLIN and DENVER - November 2, 2017 - Medtronic plc (NYSE:MDT) today presented new data at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting showcasing the excellent clinical performance of the Evolut(TM) Transcatheter Aortic Valve Replacement (TAVR) platform.

Medtronic plc (NYSE:MDT) today presented new clinical research to support the positive clinical performance of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) Platform in intermediate-risk, severe, symptomatic, aortic stenosis patients. Outcomes from the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) Trial and the Evolut R FORWARD “real-world” study were presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting, reinforcing the valve’s strong performance in healthier, more active patients.

Abbott today announced it received CE Mark for XIENCE Sierra, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system.

Cordis is Now the Exclusive U.S. Distributor of Medinol Coronary Stents